What markers track telogen effluvium?
Telogen effluvium is a reactive hair-shedding condition. This page reviews the markers and models used in research on GLP-1 receptor agonist-associated telogen effluvium, including trichogram parameters and clinical asse
What markers track telogen effluvium?
Telogen effluvium is a non-scarring, reactive hair-shedding condition in which a greater proportion of scalp hairs enter the telogen (resting) phase and are subsequently shed. It is also referred to as telogen hair loss or post-partum alopecia in the obstetric literature. The condition is classified as a hair cycle disorder rather than an inflammatory or scarring alopecia. No single molecular identifier, sequence, formula, or molecular weight defines telogen effluvium; the diagnosis is clinical and trichoscopic. In the research context covered by the evidence below, the relevant exposure is glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy, including dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists [2].
The work centres on the glucagon-like peptide 1 receptor (GLP-1R) pathway and its pharmacological agonists, with hair loss studied as a reported adverse outcome rather than as a direct receptor-mediated effect [2].
Research Studies
Trichogram parameters and GLP-1RA-associated telogen effluvium
A single-centre, open-label clinical study is evaluating whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium. Participants use the supplement for 120 days. Researchers assess hair loss, hair density, and hair growth through clinical assessments, hair measurements (trichogram), and participant questionnaires [1]. The trichogram is therefore positioned as a primary instrument for tracking changes in the proportion of hairs in telogen versus anagen phases in this population.
Clinical assessment and participant-reported outcomes in GLP-1RA-associated hair loss
In the same study design, clinical assessments and participant questionnaires are used alongside trichogram measurements [1]. This combination allows investigators to compare objective hair measurements with subjective reports of shedding severity over the 120-day supplementation period.
Hair density and hair growth as tracking endpoints
Hair density and hair growth are specified as evaluated outcomes in the ongoing trial of a dietary supplement for GLP-1-associated telogen effluvium [1]. These endpoints are distinct from shedding counts and provide a structural measure of change over time.
Pharmacological context of GLP-1RA therapies and hair loss signals
GLP-1RAs and dual GIP/GLP-1RAs are used to improve glycaemic control in patients with type 2 diabetes mellitus; some of these drugs are also used to help with weight loss. Safety signals concerning a possible link between GLP-1RA therapies and hair loss have been emerging in the USA. Prescription volumes for these drugs are increasing in Europe, and the number of cases of GLP-1RA-associated hair loss is expected to increase in Europe over the coming years [2].
Population and exposure in GLP-1RA hair loss research
The commentary evidence addresses patients on GLP-1 receptor agonists, including those with type 2 diabetes mellitus and those using these drugs for weight loss [2]. The interventional study evidence is limited to women with GLP-1-associated telogen effluvium [1].
| Marker or endpoint | Study population | Source |
|---|---|---|
| Trichogram (hair measurements) | Women with GLP-1-associated telogen effluvium | [1] |
| Hair loss (clinical assessment) | Women with GLP-1-associated telogen effluvium | [1] |
| Hair density | Women with GLP-1-associated telogen effluvium | [1] |
| Hair growth | Women with GLP-1-associated telogen effluvium | [1] |
| Participant questionnaires | Women with GLP-1-associated telogen effluvium | [1] |
Duration of tracking in the interventional study
The supplement is used for 120 days in the ongoing study, with hair loss, hair density, and hair growth evaluated through clinical assessments, trichogram, and questionnaires [1]. No results are reported in the evidence provided.
Evidence limitations
The evidence block contains no animal-only or in vitro data on telogen effluvium markers. The interventional study is open-label and single-centre, and no outcome data are available [1]. The commentary describes safety signals and pharmacological context but does not report marker validation data [2].
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.